Vaqar Ahmad, MD
Endocrinology, Diabetes & Metabolism · Midwest City, OKNPI 1225062359
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,886 of the $26,823 with a category attached, or 85.3%. Novo Nordisk accounts for 91.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $12,149 and has fallen 93.4% since, to $807 in 2025. Among endocrinology, diabetes & metabolism clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $155.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$24K
- Lilly USA, LLC$339
- Mannkind Corporation$317
- Xeris Pharmaceuticals, Inc.$305
- Insulet Corporation$287
- Dexcom, Inc.$215
- plus $925 from 15 others
What the payments were for
- Speaking & faculty fees$22,88685%
- Travel & lodging$9614%
- Food & beverage$2,76910%
- Education$890%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 58 | $24,435 |
| Lilly USA, LLC | 16 | $339 |
| Mannkind Corporation | 10 | $317 |
| Xeris Pharmaceuticals, Inc. | 16 | $305 |
| Insulet Corporation | 15 | $287 |
| Dexcom, Inc. | 11 | $215 |
| Amgen(2 entities) | 9 | $165 |
| Boehringer Ingelheim | 7 | $113 |
| AstraZeneca | 4 | $78 |
| Abbott | 4 | $73 |
| Sanofi-aventis U.S. LLC | 3 | $70 |
| Ascensia Diabetes Care US Inc. | 3 | $60 |
| Ascendis Pharma Endocrinology Inc | 2 | $54 |
| Ultragenyx Pharmaceutical Inc. | 2 | $51 |
| BETA Bionics, Inc. | 2 | $51 |
| Exact Sciences | 3 | $49 |
| Corcept Therapeutics | 2 | $47 |
| Merck | 2 | $42 |
| AbbVie | 2 | $33 |
| Bayer | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,823 in reported general payments places this provider in the 90th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $67,973 |
| JardianceEmpagliflozin | 23 | $35,075 |
| TrulicityDulaglutide | 21 | $29,800 |
| FarxigaDapagliflozin Propanediol | 11 | $8,153 |
| Novolog FlexpenInsulin Aspart | 30 | $6,110 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $5,787 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $3,151 |
| SynthroidLevothyroxine Sodium | 36 | $1,685 |
| Droplet Pen NeedlePen Needle, Diabetic | 12 | $1,240 |
| Glimepiride | 45 | $449 |
| Levothyroxine Sodium | 48 | $427 |
| Metformin Hcl | 16 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $24,435 | $67,97342 claims |
| Boehringer IngelheimJardiance | $113 | $35,07523 claims |
| Lilly USA, LLCTrulicity | $339 | $29,80021 claims |
| AstraZenecaFarxiga | $78 | $8,15311 claims |
| AbbVieSynthroid | $33 | $1,68536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Midwest City
- Cassie SmithEdmond$629K
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Matthew DraelosEdmond$110K
- Christian MangrumOklahoma City$54K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
- Robert ScofieldOklahoma City$15K
- Lubna MirzaNorman$12K
- Donny WynnOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.